Case Report
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2018; 6(14): 854-861
Published online Nov 26, 2018. doi: 10.12998/wjcc.v6.i14.854
Intralesional and topical glucocorticoids for pretibial myxedema: A case report and review of literature
Fan Zhang, Xin-Yue Lin, Jian Chen, Shi-Qiao Peng, Zhong-Yan Shan, Wei-Ping Teng, Xiao-Hui Yu
Fan Zhang, Xin-Yue Lin, Jian Chen, Shi-Qiao Peng, Zhong-Yan Shan, Wei-Ping Teng, Xiao-Hui Yu, Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: All the authors materially participated in this work, read and approved the final manuscript; Zhang F is the first author for this study; Yu XH is the corresponding author supervising this work; Zhang F and Lin XY managed the case and drafted the manuscript; Zhang F, Lin XY, Chen J and Peng SQ performed data analysis and interpretation based on literature review; Yu XH, Shan ZY and Teng WP reviewed the manuscript; Lin XY and Chen J prepared histopathological results; All authors participated sufficiently in the work and take public responsibility for its content.
Informed consent statement: Written consent was obtained from the patient. The patient consented to the publication of medical data (including figures from diagnostic imaging results and from histological examination results).
Conflict-of-interest statement: All authors declare no conflicts of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Xiao-Hui Yu, MD, PhD, Professor, Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. yuxh@cmu1h.com
Telephone: +86-24-83283135
Received: August 8, 2018
Peer-review started: August 9, 2018
First decision: August 24, 2018
Revised: September 4, 2018
Accepted: October 12, 2018
Article in press: October 11, 2018
Published online: November 26, 2018
Processing time: 110 Days and 16.6 Hours
Core Tip

Core tip: Pretibial myxedema (PTM) is an extrathyroidal, dermatological manifestation of Graves’ disease. And PTM may be associated with autoimmunity. Local glucocorticoid therapy is the most common and effective option for PTM. However, any difference in efficacy between the external use of a glucocorticoid ointment and intralesional glucocorticoid is unclarified. Our experience with this patient suggests that multipoint subcutaneous injections of a long-acting glucocorticoid and topical glucocorticoid ointment application are safe, effective, and convenient treatments. However, the topical application of a glucocorticoid ointment is a more convenient treatment for patients with PTM.